- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07594327
Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer
Pelvic Exenteration as a Curative Option in Recurrent Gynecological Cancer: Oncological Outcomes and Impact on Quality of Life and Sexuality
Pelvic exenteration is an exceptionally extensive and very rare surgical procedure, most commonly used in the treatment of locally recurrent cervical cancer among gynecological malignancies. It is typically performed with curative intent when no other treatment options remain feasible.
The aim of this study is to examine the quality of life and sexuality of patients who have undergone pelvic exenteration.
This observational cross-sectional study utilizes internationally validated questionnaires assessing quality of life and sexual function: EORTC QLQ-C30, EORTC QLQ-CX24, and PISQ-12.
The findings of this study will provide important guidance for the selection and planning of pelvic exenteration. Improved understanding of postoperative quality of life will support patient selection and enable more comprehensive and individualized patient counseling.
Visão geral do estudo
Status
Descrição detalhada
The investigators will invite living patients who have undergone pelvic exenteration for gynecological cancer at Tampere University Hospital since January 1, 2000, to participate in the study, provided that at least six months have elapsed since the surgery.
The patients are first contacted by telephone to inform them about the study. The investigators will then send an information letter regarding participation, along with questionnaires assessing quality of life and sexuality. There are 21 living patients, most of whom have had cervical cancer. Particular interest will be given to patients who have undergone neovaginal reconstruction, and additional sexuality-related questions have been developed specifically for these patients.
In addition, the medical records of all patients who have undergone pelvic exenteration for gynecological cancer since January 1, 2000, are retrospectively reviewed. Oncological outcomes after pelvic exenteration, factors affecting prognosis, and postoperative complications are assessed.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
-
Tampere, Finlândia
- Tampere University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- patient age over 18 years
- a diagnosis of gynecologic cancer
- having undergone exenteration surgery on or after January 1, 2000 (at least 6 months prior)
- the ability to read and write Finnish
Exclusion Criteria:
- cognitive and/or neurological disease that affects physical functioning and may therefore influence sexual functioning or make it difficult to respond to the questionnaire
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Self-reporterd quality of life measured by EORTC QLQ-C30 questionnaire
Prazo: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
The EORTC QLQ-C30 is a 30-item questionnaire measuring the quality of life (QoL) of cancer patients, developed by the European Organisation for Research and Treatment of Cancer (EORTC).
It assesses physical, psychological, and social functioning.
|
Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
|
Self-reporterd quality of life measured by EORTC QLQ-CX24 questionnaire
Prazo: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
The EORTC QLQ-CX24 is a 24-item questionnaire, designed to assess disease-specific and treatment-specific aspects of quality of life in patients with cervical cancer.
It is developed by the European Organisation for Research and Treatment of Cancer (EORTC).
|
Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
|
Self-reported sexuality assessed by the PISQ-12 questionnaire with additional study-specific questions
Prazo: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
The PISQ-12 questionnaire is designed for patients with urinary incontinence or pelvic organ prolapse.
However, it also includes useful questions for patients undergoing pelvic exenteration.
In addition, the investigators have developed and included their own questions specifically tailored for patients with a neovagina.
|
Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças uterinas
- Doenças Genitais Femininas
- Neoplasias Genitais Femininas
- Doenças do colo do útero
- Neoplasias uterinas
- Doenças vulvares
- Doenças vaginais
- Comportamento
- Comportamento sexual
- Neoplasias do colo uterino
- Neoplasias endometriais
- Neoplasias vulvares
- Neoplasias Vaginais
- Sexualidade
Outros números de identificação do estudo
- R25065
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .